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ABSTRACT 
 
Due to the high prevalence rates of cigarette smoking and asthma, current and former smokers 
frequently develop chronic airway disease without spirometric evidence of COPD, either alone 
or associated with asthma. This review considers the classification, clinical outcomes, 
inflammatory and imaging variables, phenotypes and management of current and former 
smokers with airway disease without COPD, focusing on overlaps in those with and without 
asthma. These individuals have more respiratory symptoms, worse quality of life, increased 
exacerbation rates, reduced lung function and more comorbidities than never smokers with 
asthma or healthy never smokers. As well as clinical features, airway inflammatory and 
structural changes in smoking-induced airway disease without COPD overlap with those found 
in smokers with asthma. Cigarette smoking is associated with worse clinical outcomes in some 
phenotypes of asthma. Management involves public health measures to control exposure to 
tobacco smoke, personal advice on smoking cessation and the use of appropriate targeted 
therapies, although evidence is limited on their effectiveness. Understanding the mechanisms, 
natural history and management of current and former smokers with asthma and smoking-
induced airway disease without COPD is a priority for future research. 
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INTRODUCTION 
 
The asthma-COPD overlap syndrome (ACOS) is a term recently introduced to describe people 
with features of both asthma and COPD [1, 2]. The definition is imprecise [3], since it is based 
on assessing the probability that clinical characteristics of both asthma and COPD are present in 
a patient with chronic airflow obstruction, defined as an FEV1/FVC ratio <0.7. The overlap 
syndrome is associated with worse clinical outcomes compared to COPD alone, including more 
severe symptoms, worse quality of life, more frequent exacerbations, greater decline in lung 
function, increased mortality and higher health care costs [1, 2, 4, 5]. Estimates of the 
prevalence of ACOS range from 15% to around 50% of patients with chronic airflow obstruction. 
ACOS is an umbrella term that describes a collection of phenotypes and endotypes of chronic 
airway disease, including subgroups with type 2 inflammation and eosinophilia [6]. Cigarette 
smoking is an important risk factor associated with the development of COPD and ACOS [7, 8]. 
Smoking-induced airway disease in people who do not have spirometric evidence of COPD is 
also recognized, either alone or in association with asthma. These subgroups of chronic airway 
disease with normal lung function are likely to occur commonly, due to the high prevalence 
rates for cigarette smoking and asthma in most populations. Worldwide over 1 billion people 
are estimated to use tobacco products, mainly through smoking cigarettes and over 300 million 
have asthma. In many countries the proportion of cigarette smokers among people with 
asthma is similar to the general population [9], although in the US, a higher percentage of 
people with asthma are smokers (21%) than among those without asthma (16.8%) [10]. 
Smoking-induced effects on the lungs, such as chronic bronchitis, emphysema, gas trapping and 
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small airway disease can occur in the absence of chronic airflow obstruction. Taken together, 
these findings suggest that chronic respiratory symptoms in current or former cigarette 
smokers without spirometric evidence of COPD could be due to asthma, smoking-induced 
airway disease or a combination of these conditions.  This review considers the classification, 
clinical outcomes, inflammatory and imaging variables, phenotypes and management of 
current and former smokers with airway disease without COPD, including those with and 
without asthma and focuses on the overlaps between these subgroups.  
 
EPIDEMIOLOGICAL AND CLINICAL STUDIES 
 
Epidemiological studies in the general population, observational studies of volunteers recruited 
to large cohorts used to investigate COPD and studies of people with asthma in primary and 
secondary care provide information to help classify chronic airway disease in current and 
former cigarette smokers without spirometric COPD, including those who also have asthma and 
to describe clinical, inflammatory and imaging variables in these individuals. Epidemiological 
studies of people randomly selected from the general population include the  US Third National 
Health and Nutrition Examination Surveys (NHANES III) in 1988-94 and 2007-2010 [11-13], the 
Canadian Cohort of Obstructive Lung Disease (CanCOLD) study in nine urban sites in Canada 
[14] and the New Zealand Wellington Respiratory Survey [15]. Information on current and 
former smokers without COPD is provided from subgroups of middle age and older volunteers 
recruited to the Genetic Epidemiology of COPD (COPDGene) study [16] and the Subpopulations 
and Intermediate Outcome Measures in COPD Study (SPIROMICS) [17, 18]. Both studies 
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included individuals with a concomitant diagnosis of asthma. Data on current and former 
smokers with a diagnosis of asthma are based on epidemiological studies in the general 
population, such as the Copenhagen General Population Study [19] and studies in primary care 
and secondary care [20-23].  Several important issues about methodology influence the 
interpretation of the evidence provided by these studies (Table 1), such as differences in 
demographic factors between study populations, uncertainty about the diagnosis of the type of 
chronic airway disease, variations in exposure to tobacco smoke, differences in the methods 
used to assess clinical outcomes and generalizability of the findings.  
 
CLASSIFICATION OF CHRONIC AIRWAY DISEASES IN SMOKERS WITHOUT COPD 
 
The ability to classify smoking-induced airway disease without spirometric COPD, with or 
without features of asthma, is hampered by the relatively small number of published studies, 
the methodological factors discussed above and by a limited understanding of the phenotypes, 
endotypes and mechanism of airway disease in these subgroups. Epidemiological studies of 
middle aged and older individuals without spirometric evidence of COPD, approximately half of 
whom are current or former smokers [12-15, 19], suggest that 14% to 20% have chronic airway 
disease, mainly due to asthma, chronic bronchitis or a combination of these diseases. A small 
proportion have emphysema alone, although this increases to one-third in heavy cigarette 
smokers [24]. In the COPDGene [16] and SPIROMICS [17] cohorts of symptomatic and 
asymptomatic middle aged and older current and former smokers with normal spirometry, 
11.4% and 18% respectively had a history of asthma, 12.6% and 18% had chronic bronchitis and 
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10.4%, and 0% had computed tomography (CT) emphysema. Among the symptomatic current 
and former smoker sub-groups, many had airway disease not associated with a history of 
asthma, although around one third had asthma, one third had chronic bronchitis and a small 
proportion had a combination of these conditions. Cluster analysis performed in two Korean 
cohorts of patients with asthma that included current smokers, identified a ‘smoking asthma’ 
cluster that was predominately male and had well preserved FEV1  [25].   
 
A classification of chronic airway disease is proposed for symptomatic current and former 
smokers without airflow obstruction (Figure 1). Smoking-induced airway diseases include 
chronic bronchitis, emphysema, small airway disease or a combination of these diseases [26, 
27] and these conditions occur in people who also have a diagnosis of asthma. Some individuals 
may have undiagnosed asthma or other smoking-induced abnormality not detected by current 
techniques. Chronic respiratory symptoms in current and former smokers with asthma may be 
due to mechanisms induced by asthma, by smoking or by a combination of both pathways. 
Cigarette smoking is a risk factor for cardiovascular co-morbidities, increased mortality and the 
development of asthma in adults [27, 28]. Risk factors implicated in causing COPD other than 
cigarette smoking [29], including exposure to biomass fuels, occupational agents and air 
pollution as well as to impaired lung growth in childhood and poverty [1, 29] may contribute to 
airway damage in current and former smokers with normal spirometric lung function or with 
asthma. Lung disorders, such as interstitial lung disease or non-respiratory conditions, such as 
cardiac disease or high BMI can be alternative causes of symptoms in current and former 
smokers and these disorders can occur in addition to chronic airway disease.  
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In summary, classification of asthma and smoking-related diseases in current and former 
smokers without evidence of spirometric COPD will require to be revised in the light of future 
studies that provide a greater understanding of the underlying phenotypes and endotypes of 
chronic airway disease in these individuals. 
 
CLINICAL OUTCOMES  
 
Similarities and differences in clinical outcomes in current and former smokers with chronic 
airway disease without spirometric COPD or a history of asthma are compared with current and 
former smokers with asthma (Table 2).  
 
Chronic respiratory symptoms 
 
Chronic respiratory symptoms of wheezing and dyspnoea are experienced by between 15% and 
30% of adults aged >40 years or greater in the general population, particularly in current and 
former smokers [12, 14, 15]. In the COPDGene and SPIROMIC cohorts, a history of wheezing, 
breathlessness or limitation of exercise was reported by approximately half the current and 
former smokers without COPD [16, 17, 30]. In the symptomatic subgroup of the SPIROMIC 
study, a high proportion reported wheezing (69%) and had a diagnosis of asthma (27%) [17]. 
Surveys of people with asthma, including those with severe disease, demonstrate that current 
smoking is an important risk factor for poor symptom control including wheezing and 
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breathlessness [19, 20, 31, 32] and these individuals often report limitations in exercise 
tolerance. 
 
The prevalence rate for chronic bronchitis  in the general population is 6.4% [33], with higher 
rates in smokers without airflow obstruction [34, 35], including adults aged >40 years or greater 
[12, 14, 15].  Chronic bronchitis was reported by 12.6% and 19% of current and former smokers 
with normal spirometry recruited to COPDGene [16] and SPIROMICS cohorts [17] respectively, 
with a higher proportion reporting chronic bronchitis among  symptomatic individuals (33%) 
[17]. There is relatively limited information on the prevalence of chronic bronchitis in asthma 
[35-39]. The Copenhagen City Heart Study and the European Community Respiratory Health 
(ECRH) survey reported prevalence rates of 39% and 42% respectively in non-smokers with 
asthma [35, 37], with higher rates in smokers with asthma [35, 37], particularly those with 
severe disease [39]. Smoking-induced chronic bronchitis without COPD is a risk factor for 
respiratory exacerbations [14] and is associated with worse quality-of-life, reduced exercise 
tolerance and a higher pack-year history [40]. In smokers with asthma, chronic bronchitis is 
associated with worse current symptom control [39] and a greater decline in FEV1  [35]. 
 
Quality of life 
 
Health-related quality of life is poorer in adults aged >40 years or greater without a diagnosis of 
asthma, emphysema or COPD who gave a history of exacerbations than those without 
exacerbations [14]. In the COPDGene cohort, current and former smokers without spirometric 
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COPD had worse health status as assessed by the St. George's Respiratory Questionnaire 
(SGRQ) total score than healthy never smokers [16]. In some surveys, smokers with asthma had 
worse levels of asthma-specific quality of life than never smokers with asthma [41].  
 
Exacerbations and health care utilization  
 
In the CanCOLD general population study, approximately 4% of individuals without evidence of 
COPD or a history of asthma had an exacerbation in the last year [14] and these events were 
associated with female gender, presence of wheezing, the use of respiratory medications and 
self-perceived poor health. A five-year follow-up of the COPDGene cohort reported that 4.1% of 
current and former smokers without COPD had one or more exacerbations per year and 
approximately 1% has a severe exacerbation requiring hospital admission [42]. Risk factors for 
acute episode of respiratory disease in smokers without COPD are similar to those with COPD, 
although the rate of episodes is higher in the latter group [43]. In the SPIROMIC population, 
symptomatic current and former smokers more often had exacerbations (0.27 events per year) 
than asymptomatic current or former smokers (0.08 events per year) or never smokers (0.03 
events per year) [17]. Current smoking is a risk factor for severe asthma exacerbations [27] 
including during pregnancy [44] and in severe disease [31], more hospitalization for asthma 
[41], more visits to the  emergency room for asthma [45] and increased numbers of life 
threatening asthma attacks. In contrast, the Copenhagen General Population Study reported 
that the risk of asthma exacerbations was unrelated to smoking status [19].  
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Lung function 
 
Spirometric lung function tests are reduced in cigarette smokers without a history of lung 
disease compared with never smokers [1], in symptomatic current or former smokers without 
COPD compared with asymptomatic current or former smokers [17] and in smokers with 
asthma compared with never-smokers with asthma [19, 31, 46]. Small airway dysfunction 
occurs in current and former smokers without COPD, irrespective of the presence or absence of 
respiratory symptoms [18] and its presence is associated with a more rapid decline in lung 
function [47]. Tests of small airway function are also impaired in smokers with asthma [46]. In 
the COPDGene cohort, current and former smokers without spirometric COPD (FEV1/FVC 
greater than lower limit of normal) had abnormal forced expiratory volume in 3 and 6 seconds 
(FEV3/FEV6) ratios that identified individuals with mild COPD characterised by CT small airway 
disease, impaired exercise tolerance and reduced quality of life [48].   In a five year follow-up of 
the COPDGene cohort, the rate of FEV1 decline was similar in current and former smokers 
without COPD who reported breathlessness or exacerbations compared to those who did not  
[42]. Several longitudinal population-based studies report accelerated decline in lung function 
in adult smokers  with asthma [35, 49, 50], although other studies report a similar decline in 
FEV1 in asthma irrespective of smoking status [37]. A greater proportion of smokers with adult-
onset asthma develop persistent airflow obstruction and although current smokers with a 
history of childhood-onset asthma can develop COPD, this occurs in association with severe 
disease in childhood rather than cigarette smoking in adulthood [51, 52]. 
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Corticosteroid insensitivity 
 
Corticosteroid insensitivity occurs in chronic inflammatory diseases including severe asthma 
and COPD [53, 54]. The effects of budesonide on epithelial barrier function in primary bronchial 
epithelial cells is impaired in asthma and COPD and this effect is less evident in healthy 
smokers, suggesting that corticosteroid responsiveness in smokers without spirometric 
evidence of COPD might be better preserved than in those with COPD [55], although this 
hypothesis remains to be tested in clinical studies. Cigarette smokers with mild to moderate 
asthma are less sensitive to the short and medium-term therapeutic effects of inhaled 
corticosteroids on symptoms and lung function compared to non-smokers with asthma [21, 56, 
57]. Smokers with chronic asthma are also less sensitive to short-term oral corticosteroid 
therapy [58] and to the cutaneous vasoconstrictor response to topical corticosteroids [59]. Data 
is conflicting on whether the long-term therapeutic effects of inhaled corticosteroids are 
impaired in smokers with asthma [60-64]. Taken together, these studies suggest that most 
smokers with asthma are less sensitive to short and medium treatment with inhaled 
corticosteroids compared to non-smokers with asthma, but that a small proportion of smokers 
can respond adequately to this treatment and that long-term treatment may have beneficial 
effects.  
 
Comorbidities and mortality 
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Cigarette smoking is a risk factor for diseases that can impact on the health of smokers with 
asthma or smoking-induced airway disease without COPD, such as cardiovascular disease [65], 
anxiety and depression, and osteoporosis. In the US Multi-Ethnic Study of Atherosclerosis 
(MESA) study, greater emphysema-like changes on cardiac CT were associated with increased 
all-cause mortality among people without airflow obstruction, particularly among smokers [66]. 
Co-morbidities occur frequently in smokers with asthma, with higher rates of cardiovascular 
disease, pneumonia and lung cancer compared to never smokers without asthma [19]. Patients 
with adult-onset asthma, at least one comorbidity and evidence of systemic inflammation, 
characterised by elevated levels of interleukin (IL)-6 and high-sensitivity C-reactive protein 
(hsCRP,) had a higher pack-year history than patients without systemic inflammation or a co-
morbidity [67]. The US National Health and Nutrition Examination Survey Epidemiologic Follow-
up Study (NHEFS) reported  an increased risk of respiratory mortality and all-cause mortality in 
asthma that may be explained by the confounding effect of cigarette smoking [68].  
 
Clinical outcomes in former smokers 
 
In the COPDGene cohort, former smokers had less chronic respiratory symptoms, fewer 
exacerbations and less airway wall area thickening plus greater emphysema and gas trapping 
than current smokers [16]. In the SPIROMICS cohort, the proportion of current smokers with 
chronic respiratory symptoms and exacerbations was similar to the former cigarette smokers 
[17]. In most studies, former smokers with asthma had levels of symptom control, chronic 
bronchitis, quality of life and health care use for asthma that were either similar or worse than 
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never-smokers with asthma and that were generally better than current smokers with asthma 
[20, 31, 37, 41, 69]. In one study of people with severe asthma, increased blood neutrophil 
counts in former smokers with a low pack year history were associated with frequent 
exacerbations, whereas elevated blood eosinophils predicted exacerbations in never smokers 
[70]. The Copenhagen General Population Study reported that the frequency of any respiratory 
symptoms was not associated with smoking status in individuals with asthma [19].  All-cause 
mortality  and rates of cardiovascular disease, pneumonia and lung cancer  in former smokers 
with asthma were similar to never smokers and current smokers with asthma [19].   
 
In summary, current and former smokers without COPD have more chronic respiratory 
symptoms, worse quality of life, increased exacerbation rates, reduced lung function and more 
comorbidities than never smokers without COPD. There is considerable overlap in the range 
and frequency of adverse clinical outcomes between those with and without a diagnosis of 
asthma.  
 
INFLAMMATORY AND IMAGING VARIABLES  
 
Cigarette smoking and asthma induce distinct inflammatory and structural changes to the lungs, 
although less is known about whether these stimuli interact. Tobacco smoke induces pro-
inflammatory responses in the lungs that are mediated by alveolar macrophages, neutrophils 
and respiratory epithelial cells and it also impairs innate defence mechanisms that are 
produced by alveolar macrophages, epithelial cells, natural killer cells, and dendritic cells [71]. 
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The risk of developing smoking-related inflammation increases with greater smoking intensity 
in healthy subjects [72]. The bronchial mucosa of asymptomatic smokers without COPD has 
increased inflammatory cells, including neutrophils, mast cells, and macrophages, increased 
cells staining positive for IL-1β and IL-8, reduced epithelial integrity and increased thickness of 
the laminin layer in the sub-epithelium [73, 74]. In smokers with normal lung function, it is likely 
that epithelial inflammation and glandular hyperplasia contribute to symptoms of chronic 
bronchitis, impaired inflammatory responses contribute to increased risk of infection and 
altered immunity contributes to airway damage. Published data are not available on the airway 
histology in symptomatic and asymptomatic smokers without spirometric COPD recruited to 
the COPDGene and SPIROMICS cohorts. Current smokers without COPD, but with evidence of 
small  airway dysfunction,  have evidence of distal airway inflammation [75, 76]. In the 
CanCOLD study of middle aged or older current and former smokers with normal lung function 
(mean age 68 years), the prevalence of bronchial wall thickening, air trapping and emphysema 
on visual inspection of CT scans was 58%, 35% and 30% respectively compared to never 
smokers with no obstruction [24].  CT emphysema was estimated to be mild, since it was not 
associated with worse clinical outcomes [24]. In the COPDGene cohort, approximately one-third 
of current and former smokers without spirometric COPD had segmental CT airway wall 
thickening [16].  In the SPIROMIC population, symptomatic current and former smokers without 
spirometric evidence of COPD, irrespective of a history of asthma, had greater CT airway wall 
thickening compared with asymptomatic individuals [17]. Quantitative CT and visual scoring 
emphysema was reported in 10.4% and 24% respectively of current and former smokers 
without spirometric COPD recruited to COPDGene [16].  
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In smokers with asthma, sputum airway inflammation is often reported to be non-eosinophilic, 
either neutrophilic or paucigranulocytic [21, 22, 31], although a recent study found no 
association between smoking status and sputum inflammatory phenotypes in asthma [77]. 
Differences in the intensity of smoking may explain some of the discrepancies between studies. 
Exhaled nitric oxide concentration is reduced in current cigarette smokers with asthma [31, 78], 
whereas concentrations are similar in former and never smokers with severe asthma [31]. 
Bronchial biopsy studies in smokers with mild and moderate asthma report reduced eosinophil 
numbers, increased sub-mucosal mast cell numbers [79] and increased CD8+ T lymphocytes [80] 
compared to never smokers with asthma. In addition, smokers with asthma have increased 
bronchial goblet cell numbers and more proliferation and greater thickness of the epithelium 
[79]. In the U-BIOPRED cohort of individuals with severe asthma, CD4+ lymphocyte numbers 
were reduced in current and former smokers compared to non-smokers with severe asthma 
[81].  Airway smooth muscle mass, basement membrane thickness and submucosal gland area 
are similar [79, 82]. In keeping with these latter findings, CT measure of segmental airway wall 
thickness are similar in smokers and never smokers with mild to severe asthma in [46]. CT large 
airway luminal area is reduced in smokers with severe asthma [46], particularly in those who 
gave a history of chronic mucus hypersecretion [39], possibly due to mucus accumulation in the 
large airways and to structural changes to the airways. CT emphysema is an infrequent finding 
in smokers with asthma [46]. 
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In summary, these observations suggest that tobacco-induced airway inflammatory and 
structural changes are present in smokers without spirometric COPD compared to healthy 
never smokers. Airway inflammation in smokers with asthma differs from that of never smokers 
with asthma; current smoking is associated with less eosinophilic airway inflammation, more 
mast cell numbers, increased bronchial epithelial glands and reduced segmental airway luminal 
area. Airway inflammatory and structural changes in smoking-induced airway disease without 
COPD overlap those found in smokers with asthma.  
 
PHENOTYPES  
 
Subtypes or phenotypes of  asthma are recognised, based on clinical, physiological or 
immunological variables, and these are used to classify asthma and to predict response to 
therapy [83]. Phenotypes of smoking-related disease occur in current and former cigarette 
smokers without spirometric COPD or a history of asthma, such as chronic bronchitis, 
emphysema and small airway disease (Figure 1). Current and former cigarette smoking in 
asthma is associated with worse outcomes in certain clinical phenotypes discussed earlier, such 
as chronic bronchitis, chronic persistent airflow obstruction and corticosteroid insensitivity. 
There is limited and in some cases conflicting information on the influence of current and 
former cigarette smoking on clinical and inflammatory phenotypes of asthma. 
 
Clinical phenotypes 
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Adult-onset asthma: Greater pack year history is a predictor of uncontrolled asthma, increased 
disease severity and greater decline in lung function in people with adult-onset asthma [84-88]. 
A higher proportion of people with severe adult-onset asthma are current and former smokers 
compared with severe childhood-onset asthma and the adult-onset  group have a higher pack 
year history [89].  
Allergic asthma: Total IgE concentrations in asthma are not altered by smoking status [19, 31], 
whereas specific IgE sensitization to some common environmental allergens is reduced in 
current smokers and former smokers with severe asthma compared to never smokers with 
severe asthma [31]. Smoking status of individuals with mild atopic asthma does not influence 
the magnitude of the allergen-induced early response [90, 91], whereas the magnitude of the 
late response is reported to be reduced [91] or similar  [90] in current smokers compared to 
non-smokers [91]. 
Aspirin-exacerbated respiratory disease: Active smoking in adulthood and exposure to second-
hand smoke in childhood are associated with an increased risk of developing aspirin-
exacerbated respiratory disease [92, 93]. 
Obesity-related asthma: The prevalence and intensity of current or former cigarette smoking in 
obese or non-obese individuals with severe asthma are similar [94, 95]. Both smoking and 
obesity are independent risk factors for poor asthma control and increased exacerbations [96]. 
A survey of US adults reported that current smoking  increased the risk of symptoms, 
emergency room visits and missing work days due to asthma associated with obesity or physical 
inactivity [97]. It is postulated that obesity and cigarette smoking modify the clinical expression 
of asthma in women by increasing systemic inflammation [98].   
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Occupational asthma: In a Canadian prospective observational study, the proportion of current 
and former smokers was similar between people with occupational asthma and with non-work 
related asthma [99]. Cigarette smoking at the time of diagnosis does not adversely influence 
the outcome of occupational asthma [100]. 
Chronic rhinosinusitis: In the Swedish general population, cigarette smoking is associated with a 
high prevalence of chronic rhinitis in both men and women and a low prevalence of allergic 
rhinitis in men [101]. Increased severity of sinusitis on CT imaging is associated with higher 
blood eosinophil counts, serum IgE levels, exhaled nitric oxide and serum periostin 
concentrations in both adult non-smokers (<10 pack years) and smokers with asthma (≥10 pack 
years), suggesting that CT imaging evidence of severe sinusitis was associated with type-2 high 
inflammation irrespective of smoking status [102].  
Psychological factors: Active cigarette smokers with severe asthma had higher Hospital Anxiety 
and Depression (HAD) scores than never smokers or former smokers with severe asthma, 
suggesting that these subjects were experiencing a greater degree of emotional distress [31]. In 
the general population, smoking cessation is associated with reduced depression, anxiety, and 
stress and improved positive mood and quality of life compared with continuing to smoke 
[103]. 
 
Inflammatory phenotypes 
 
Eosinophilic inflammation is a risk factor for exacerbations and predicts a beneficial response to 
corticosteroids. T helper type 2 cell (Th2)-high inflammation (Type 2 high inflammation) is 
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closely associated with eosinophilic inflammation and predicts a favourable therapeutic 
response to biological agents targeting the Th2 cytokine pathway. A non-eosinophilic phenotype 
is associated with current smoking and is poorly responsive to current therapies including 
corticosteroids [104]. Cigarette-smoking might induce a Th2-low inflammatory phenotype, 
although little is known about the prevalence or importance of Th2-low inflammation in current 
or former smoker with asthma or associated clinical asthma phenotypes. 
 
In summary, some clinical and inflammatory phenotypes of asthma are influenced by smoking 
status and different phenotypes of chronic airway disease occur in current and former cigarette 
smokers without spirometric COPD or a history of asthma. Establishing the overlap between the 
phenotypes and endotypes of asthma and smoking-induced airway disease with normal lung 
function and their influence in directing therapy requires future investigation. 
 
MANAGEMENT 
 
The management of the adverse health effects caused by exposure to tobacco smoke in people 
with asthma and in current and former smokers without spirometric evidence of COPD involves 
interventions ranging from public health measures to control exposure to tobacco smoke, 
personal advice on smoking cessation and the use of appropriate targeted therapies. Beyond 
advice on smoking cessation, there is limited information on drug treatment of smokers with 
asthma and symptomatic smokers with normal lung function [1, 2]. The management of 
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systemic smoking-induced co-morbidities, such as cardiovascular disease should be as guided 
by national and local recommendations. 
 
Smoking cessation 
 
Smoking cessation is an important goal in the management of all cigarette smokers, including 
those with asthma and symptomatic smokers with normal lung function.  There is limited 
evidence of the effectiveness of smoking cessation on clinical outcomes in asthma and most 
studies include small numbers of participants and are of short duration. In some studies, 
symptoms, lung function or corticosteroid sensitivity improve and sputum neutrophils decrease 
in those who quit smoking successfully [22, 105-108]. Former smokers with asthma have better 
symptom control than current smokers with asthma  [20, 69]. Despite the known adverse 
effects of active smoking in asthma, these individuals are no more likely to receive physician 
counselling regarding smoking cessation, nor smoking cessation pharmacotherapy compared to 
the general smoking population [109]. Smokers with asthma have poor smoking cessation rates 
[110] and slower rates of decline in nicotine withdrawal symptoms and craving during smoking 
quit attempts [111]. The effect of smoking cessation on clinical variables in symptomatic 
smokers recruited to the COPDGene or SPROMICS cohorts is not reported, although smoking 
cessation was associated with older age of participants recruited to COPDGene [16]. In a 
population of current smokers with and without COPD, chronic respiratory symptoms including 
bronchitis were associated with the intension to stop smoking in the next 30 day suggesting 
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that the presence of respiratory symptoms could be used to aid smoking cessation advice in 
smokers with normal lung function [112]. 
 
Current pharmacological treatments 
 
Evidence is limited on the effectiveness of therapeutic interventions directed at improving 
clinical outcomes due to their exclusion from most clinical trials. Studies in asthma usually 
exclude current smoker or former smoker with a smoking history of >10 pack-years and studies 
in COPD exclude symptomatic current smoker or former smokers without spirometric evidence 
of COPD or with a smoking history of <10 pack years. Clinical trials in smokers with asthma may 
provide some limited guidance on drug treatment for current and former smokers with chronic 
airway disease without COPD or asthma. Despite the presence of reduced sensitivity to low-
dose inhaled corticosteroids, higher doses improve lung function [57], although many patients 
remain symptomatic. Targeting the small airways with extrafine-particle inhaled corticosteroids 
may potentially impact favourably on the safety and efficacy of inhaled corticosteroids through 
improved total lung deposition and improved asthma control at lower daily doses than large-
particle inhaled corticosteroid. Observational studies suggest that extrafine particle 
hydrofluoroalkane (HFA)-beclometasone may achieve better control at lower prescribed doses 
than large particle inhaled corticosteroids [113], but to date, randomized controlled trials have 
not clearly demonstrated that equipotent doses of small-particle inhaled corticosteroids are 
more effective than large-particle inhaled corticosteroids. The addition of a long acting 2-
agonist to an inhaled corticosteroid improves clinical outcomes in smokers with asthma [61, 
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114, 115]. The long-acting muscarinic antagonist (LAMA) tiotropium was included in the 2015 
GINA guideline as an alternative add-on therapy for people with a history of exacerbations [2]. 
The generalizability of the findings of clinical trials of tiotropium to smokers with asthma and 
smoking-related airway disease with normal lung function is uncertain, since current smokers 
and former smokers with greater than a 10 pack-years were excluded from clinical trials of 
tiotropium in asthma and in some studies, participants had to have chronic airflow obstruction 
(post-bronchodilator FEV1 < 80% predicted and FEV1/FVC ratio <0.7)[116]. There is some 
support for the effectiveness of tiotropium in ‘real-life’ populations of asthma that include 
current and former smokers [81].  In an exploratory clinical trial in smokers with asthma, low 
dose theophylline added to inhaled corticosteroid resulted in improvement in lung function 
suggesting the restoration of corticosteroid sensitivity in those treated with the combination 
[117]. In one controlled trial, asthmatic patients with a smoking history of <11 pack years 
tended to show greater symptom control with inhaled fluticasone propionate over a 6-month 
period, whereas those with a smoking history of >11 pack years tended to show greater benefit 
with the leukotriene-receptor antagonist montelukast [118].  
 
There are no clinical trials of drug treatments in symptomatic smokers with normal lung 
function to guide management. It remains to be established whether therapies shown to be 
effective in the treatment of smokers with asthma, such as LABA and ICS combinations, will also 
benefit symptomatic smokers with normal lung function. Despite the uncertainty around drug 
treatment in this group, many symptomatic volunteers without COPD recruited to large COPD 
cohorts were taking respiratory medications. In SPIROMICS, 42% were taking bronchodilators 
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and 23% were taking inhaled corticosteroids [17] and in COPDGene, 20% used respiratory 
medications [16]. There is an unmet need for effective treatments for smokers without COPD as 
this group experience considerable disability from chronic respiratory symptoms and are at 
increased risk of exacerbations.  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
In conclusion, chronic respiratory symptoms occur in current and former smokers without 
spirometric evidence of COPD due to smoking-induced airway diseases including chronic 
bronchitis, emphysema, small airway disease or asthma or a combination of these diseases. 
These individuals are more likely to experience wheezing, breathlessness, limitation in exercise, 
chronic bronchitis, poorer quality of life, exacerbations and smoking-related co-morbidities 
than heathy never smokers. Corticosteroid insensitivity and a greater decline in lung function 
are features of the smokers with asthma subgroup. Airway inflammatory and structural 
changes in smoking-induced airway disease without COPD overlap with those found in smokers 
with asthma. Cigarette smoking is associated with worse clinical outcomes in some phenotypes 
of asthma. The management of the adverse health effects caused by exposure to tobacco 
smoke involves public health measures to control exposure to tobacco smoke, personal advice 
on smoking cessation and the use of appropriate targeted therapies. Evidence is limited on the 
effectiveness of therapeutic interventions directed at improving clinical outcomes in these 
groups of patients due to their exclusion from most clinical trials.  
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There are many uncertainties about this chronic airway group including their classification, 
mechanisms, natural history, and management [119]. Future research needs to establish what 
proportions of symptomatic current and former smokers with normal spirometry have 
smoking-induced airway disease alone or also have asthma or a mixture of subtypes of 
smoking-induced airway disease (Figure 1). In addition to the considerable overlap in clinical 
features that exits in current and former smokers with asthma and smoking-related airway 
disease without spirometric COPD, it will be important to understand the overlap in 
inflammatory mechanisms. Studies will require to recruit large numbers of current and former 
smokers from the general population and for these individuals to undergo detailed clinical, 
imaging and immunological phenotyping and endotyping including the employment of system 
biological approaches. Different subtypes may have different mechanisms for exacerbations 
and other clinical outcomes and require individualised targeted therapies. The natural history 
of different subtypes of smoking-induced airway disease with normal lung function may differ. 
It is important to know whether subtypes are predictive of the development of COPD. 
Interestingly, a 5-year follow-up of the COPDGene cohort with normal lung function found that 
acute respiratory events did not increase the decline in lung function [42]. Current smokers 
with adult-onset asthma are at risk of developing COPD, whereas although current smokers 
with a history of childhood-onset asthma can develop COPD, this appears not to be due to the 
effects of cigarette smoking [51, 52] suggesting that different clinical phenotypes of asthma 
may differ in the effects of tobacco smoke on lung function. It remains to be established 
whether the identification of asymptomatic patients with smoking-induced airway diseases and 
normal lung function will lead to improved outcomes [120]. Research is required to determine 
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the benefit of therapeutic interventions in this symptomatic population, particularly those at 
increased risk of exacerbations. Drugs that could be assessed for efficacy in symptomatic 
smokers with normal lung function include therapies currently used in the treatment of COPD, 
such as long-acting bronchodilators, azithromycin and roflumilast as well as other novel 
therapies under development [106]. In the future, the entry criteria for clinical trials should 
reflect ‘real life’ populations that including current and former smokers of differing ages and 
smoking intensity.  
KEY MESSAGES 
 Due to the high prevalence of cigarette smoking and asthma, current and former smokers 
frequently develop chronic airway disease without spirometric evidence of COPD, either 
alone or in association with asthma.  
 Adverse health-related outcomes occur due to smoking-induced airway diseases (chronic 
bronchitis, emphysema, small airway disease), asthma, or a combination of these diseases.   
 Current and former smokers without COPD, either with or without asthma, have more 
respiratory symptoms, worse quality of life, increased exacerbation rates, reduced lung 
function and more comorbidities than never smokers with asthma or healthy never smokers 
 As well as clinical features, airway inflammatory and structural changes in smoking-induced 
airway disease without COPD overlap with those found in smokers with asthma. 
 Cigarette smoking is associated with worse clinical outcomes in some phenotypes of 
asthma. 
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 Management involves public health measures to control exposure to tobacco smoke, 
personal advice on smoking cessation and the use of appropriate targeted therapies, 
although evidence is limited on the effectiveness of therapeutic interventions. 
 Understanding the mechanisms, natural history and management of current and former 
smokers with airway disease without spirometric evidence of COPD, either alone or in 
association with asthma is a priority for future research. 
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 Table 1. Methodological issues that influence the interpretation of studies of adults with 
asthma and smoking-induced airway disease without spirometric evidence of COPD 
Demographic information:  
 Adult participants recruited to clinical studies of smokers with asthma are generally younger than 
those included in epidemiological studies in the general population and COPD cohorts were 
participants are middle aged and older.  
 Gender and race of participants may not be representative of the general population. 
 
Diagnosis of chronic airway disease:  
 Establishing an accurate diagnosis of asthma, smoking-induced airway disease without asthma, 
chronic bronchitis, emphysema or a combination of airway diseases can be difficult in a symptomatic 
current and former smoker without spirometric COPD.  
 Asthma and other airway diseases may be underdiagnosed or misdiagnosed in observational studies 
that are based on history alone and without objective tests.  
 The specificity of objective criteria used to diagnose asthma may not be sufficient to exclude people 
with symptomatic smoking-induced airway disease who do not have asthma.  
 Observational studies in asthma can often report outcomes that combine data from smokers with 
and without chronic airflow obstruction (FEV1/FVC ratio <0.7), making it harder to assess the findings 
in those without spirometric COPD.  
 Undiagnosed emphysema and air trapping can occur in cigarette smokers without spirometric COPD 
and these conditions may be missed by spirometry and only become evident with additional tests of 
lung functions (transfer-factor; whole-body plethysmography, impulse oscillatory, multiple-breath 
washout tests) and imaging techniques (low-dose computed tomography).  
 Studies may include people with other chronic respiratory diseases, such as bronchiectasis.  
 Spirometric measurements can vary over time resulting in an individual being considered not to have 
COPD on recruitment to a study, when subsequent tests demonstrate airflow obstruction.  
 The influence of factor(s) inducing airway disease other than tobacco smoke, such as occupational 
agents and environmental exposures are not controlled in most studies.  
 Symptoms due to upper airway disease can be misdiagnosed as being due to lower airway disease.  
 
Smoking status:  
 Combined data from current smokers and former smokers may obscure differences in outcomes in 
one or another smoking group.  
 Findings in studies with an entry criteria of a smoking history of >10 pack-years, such as COPDGene 
and SPIROMICS may not be relevant to those with a less intense history of exposure to tobacco 
smoke.  
 Factors relating to smoking behavior, such as number of puffs per cigarette, depth of inhalation and 
types of cigarette may not be reflected by history of pack-years and current smoking status. 
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Assessment of clinical outcomes:  
 Measures of current symptoms and quality of life in smokers with asthma, such as the Asthma 
Control Test (ACT), Asthma Control Questionnaire (ACQ) and Asthma Quality of Life (AQLQ) scores 
can overlap with those used to measure chronic respiratory symptoms and health status in smoking-
induced airway disease with or without COPD, such as the COPD Assessment Test (CAT) and St 
George's Respiratory Questionnaire score (SGQS). For example, the SGQS is associated with changes 
in AQLQ and by some treatments for asthma, such as mepolizumab, and concomitant asthma can 
confound CAT scores in current or former smokers [121].  
 Definition of chronic bronchitis varies between studies and in some, is based on components of the 
SGQS.  
 Definition of severe exacerbation in asthma, which is based on the use of high dose systemic 
corticosteroid for 3 days or longer, either alone or associated with an emergency department visit or 
hospital admission overlaps with components of the definition of exacerbation-like respiratory 
symptoms used in studies of smoking-induced airway disease with or without COPD.  
 In observation studies, the assessment of clinical outcomes can be influenced by recall bias.  
 Age-of onset of asthma influences the effects of cigarette smoking on lung function and possibly 
other variables. 
 
Generalizability of findings:  
 The selection process and criteria used to recruit participants to studies of airway disease in 
individuals without COPD may not be generalizable to the general population, although baseline 
demographic and clinical variables in the COPDGene study showed some similarities to those in the 
NHANES study in the general population [16]. 
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Table 2. Summary of the effects of smoking status on clinical outcomes in asthma and 
symptomatic smokers without spirometric COPD* 
 
 
 
 
Outcome 
 
Asthma with a smoking history  
and without spirometric COPD  
 
 
Smoking-induced airway disease  
without spirometric COPD  
(no history of asthma) 
 
 
Current smokers with asthma compared  
with never smokers with asthma 
 
Current and former smokers compared 
with ‘healthy’ never smokers 
 
 
Respiratory symptoms  
  
 Wheeze, breathlessness 
 
 Exercise tolerance 
 
 Chronic bronchitis 
 
 
 
 
Increased 
 
Decreased 
 
Increased 
 
 
 
Increased 
 
Decreased 
 
Increased 
 
Quality of life 
 
 
Decreased or similar 
 
Decreased 
 
Exacerbations 
 
 
Increased or similar 
 
Increased 
 
Health care utilization 
 
 
Increased 
 
Increased 
 
Lung function 
  
 Baseline spirometry 
  
 Small airway dysfunction 
  
 Decline in FEV1 
  
 
 
 
Decreased 
 
Increased 
 
Increased or similar 
 
 
 
Decreased 
 
Increased 
 
Similar 
 
 
 
Therapeutic response to 
inhaled corticosteroids 
  
 Short to medium term 
treatment 
  
 Long-term treatment 
  
 
 
 
 
Decreased 
 
 
Decreased or similar 
 
 
 
 
- 
 
 
- 
44 
 
 
Smoking-related 
comorbidities 
 
 
Increased 
 
Increased 
 
All-cause mortality 
 
 
Increased 
 
Increased 
 
*Refer to the main text for information on the published studies used to summarize the effects of smoking status 
on clinical outcomes in asthma and symptomatic smokers without spirometric COPD. Symbol:  -, not known 
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FIGURE LEGEND 
 
Figure 1: Classification of chronic airway diseases in symptomatic current and former smokers 
without spirometric airflow obstruction (FEV1/FVC ratio <0.7) due to smoking-induced airway 
disease without a history of asthma, asthma-induced airway disease or an overlap of both 
diseases.  
 
Symbol ‘?’: It is not known whether current and former smokers with smoking-induced airway 
disease without evidence of COPD or a history of asthma have clinical evidence of 
corticosteroid insensitivity. 
 
 
 
 
 
 
 
